COMP <GO>
RXRX vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Recursion Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: RXRX 2
— MRK 12
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: MRK
LAST: $4.03 (-4.95%) • MKT CAP: $2.53B
options-implied-move
6.90%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXRX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXRX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.00% | 74.80% | -69.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.95% | 3.42% | -18.37 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 26.90% | 1.30% | +25.60 | RXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.59 | 5.19 | -3.60 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.6 | 56.9 | -4.27 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.92 | +0.08 | RXRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 18.4x | +13.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.53B | $361.02B | -$358.49B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXRX REV | MRK REV | RXRX GROSS % | MRK GROSS % | RXRX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $74.7M | $65.01B | 5.0% | 74.8% | -$378.3M | $12.36B |
| FY 2024 | $58.8M | $64.17B | 23.1% | 76.3% | -$372.9M | $18.10B |
| FY 2023 | $44.6M | $60.12B | 44.0% | 44.0% | -$289.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXRX // BETA 1.00
MRK // BETA 0.92